STOCK TITAN

HCA Healthcare Reports Third Quarter 2021 Results; Revises 2021 Guidance

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

HCA Healthcare reported strong third-quarter results for 2021, with revenues of $15.276 billion, up from $13.311 billion in 2020. Net income soared to $2.269 billion, or $7.00 per diluted share, compared to $668 million or $1.95 per diluted share last year. Adjusted EBITDA rose to $3.224 billion. Despite increased admissions (6.8%) and emergency room visits (31.2%), inpatient surgeries declined by 4.9%. HCA also declared a quarterly dividend of $0.48 per share. The company revised its 2021 guidance, expecting revenues between $58.7 billion and $59.3 billion.

Positive
  • Revenue increase from $13.311 billion to $15.276 billion YoY.
  • Net income jumped to $2.269 billion, from $668 million YoY.
  • Adjusted EBITDA increased to $3.224 billion, up from $2.053 billion YoY.
  • Same facility admissions grew by 6.8%, and emergency room visits surged by 31.2%.
  • Quarterly dividend declared at $0.48 per share.
  • Revised 2021 guidance for revenues set between $58.7 billion and $59.3 billion.
Negative
  • Inpatient surgeries declined by 4.9% YoY.
  • Cash flows from operating activities decreased from $2.717 billion to $2.277 billion YoY.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2021.

Key third quarter metrics (all percentage changes compare 3Q 2021 to 3Q 2020 unless otherwise noted):

  • Revenues totaled $15.276 billion
  • Net income attributable to HCA Healthcare, Inc. totaled $2.269 billion, or $7.00 per diluted share
  • Adjusted EBITDA totaled $3.224 billion
  • Cash flows from operating activities totaled $2.277 billion
  • Same facility admissions and same facility equivalent admissions increased 6.8 percent and 9.3 percent, respectively

“During the third quarter we experienced the most intense surge yet of the pandemic, and our colleagues and physicians delivered record levels of patient care to meet the demand caused by the Delta variant,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “Once again, the disciplined operating culture and strong execution by our teams were on display. I want to thank them for their tremendous work and dedication to serving others.”

Revenues in the third quarter of 2021 increased to $15.276 billion, compared to $13.311 billion in the third quarter of 2020. Net income attributable to HCA Healthcare, Inc. totaled $2.269 billion, or $7.00 per diluted share, compared to $668 million, or $1.95 per diluted share, in the third quarter of 2020. Results for the third quarter of 2021 include gains on sales of facilities of $1.047 billion, or $2.43 per diluted share, related to the sale of four hospitals in Georgia and other health care entity investments. Results for the third quarter of 2020 included a reversal of $822 million, or $1.72 per diluted share, in government stimulus income recorded in the second quarter of 2020 related to general distribution funds received from the Provider Relief Fund established by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act and $14 million, or $0.03 per diluted share, of gains on sales of facilities.

For the third quarter of 2021, Adjusted EBITDA totaled $3.224 billion, compared to $2.053 billion in the third quarter of 2020. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions and equivalent admissions increased 6.8 percent and 9.3 percent, respectively, in the third quarter of 2021, compared to the prior year period. Same facility emergency room visits increased 31.2 percent in the third quarter of 2021, compared to the prior year period. Same facility inpatient surgeries declined 4.9 percent, and same facility outpatient surgeries increased 6.4 percent in the third quarter of 2021, compared to the same period of 2020. Same facility revenue per equivalent admission increased 5.2 percent in the third quarter of 2021, compared to the third quarter of 2020, due to increases in acuity of patients treated and favorable payer mix in the quarter.

Because of the pandemic-related impact on volumes in the third quarter of 2020, the Company believes a comparison of volume statistics to the comparable period in 2019 provides additional context to the improvement in operations during 2021. The following table provides a summary of statistical measures for the third quarter of 2021 compared to the same period in 2019 on a same facility basis.

 

Third Quarter

 

2021

2019

% Change

 
 
Same Facility:
Admissions

531,032

 

517,151

 

2.7

%

Equivalent Admissions

892,665

 

897,774

 

-0.6

%

 

 

 

 

 

Patient Days

2,836,248

 

2,482,756

 

14.2

%

Equivalent Patient Days

4,767,733

 

4,310,064

 

10.6

%

 

 

 

 

 

Inpatient Surgery Cases

125,533

 

141,313

 

-11.2

%

Outpatient Surgery Cases

242,450

 

241,019

 

0.6

%

 

 

 

 

 

Emergency Room Visits

2,301,968

 

2,198,357

 

4.7

%

 
 

Nine Months Ended September 30, 2021

Revenues for the nine months ended September 30, 2021 totaled $43.688 billion, compared to $37.240 billion in the same period of 2020. Net income attributable to HCA Healthcare, Inc. was $5.142 billion, or $15.43 per diluted share, compared to $2.328 billion, or $6.79 per diluted share, for the first nine months of 2020. Results through September 2021 include gains on sales of facilities of $1.057 billion, or $2.39 per diluted share, and losses on retirement of debt of $12 million, or $0.03 per diluted share. Results for the nine months ended September 30, 2020 included losses on sales of facilities of $6 million, or $0.03 per diluted share, and losses on retirement of debt of $295 million, or $0.66 per diluted share.

Balance Sheet and Cash Flows from Operations

As of September 30, 2021, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $1.027 billion, total debt of $32.299 billion, and total assets of $49.562 billion. During the third quarter of 2021, capital expenditures totaled $889 million, excluding acquisitions. Cash flows provided by operating activities in the third quarter totaled $2.277 billion, compared to $2.717 billion in the third quarter of 2020.

During the third quarter of 2021, the Company repurchased 9.605 million shares of its common stock at a cost of $2.329 billion. The Company had $2.658 billion remaining under its repurchase authorization as of September 30, 2021. As of September 30, 2021, the Company had $5.920 billion of availability under its credit facilities.

Dividend

HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.48 per share on the Company’s common stock. The dividend will be paid on December 29, 2021 to stockholders of record at the close of business on December 14, 2021.

The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.

2021 Revised Guidance

The 2021 guidance ranges for the year have been revised from our second quarter release and are as follows:

 

2021 Guidance Range

Revenues

$58.7 to $59.3 billion

Adjusted EBITDA

$12.50 to $12.80 billion

EPS (diluted)

$17.20 to $17.80 per diluted share

Capital Expenditures

Approximately $3.7 billion

The Company’s 2021 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding the impact of the COVID-19 pandemic and related government legislation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.

Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.

The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”

Earnings Conference Call

HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed at: https://investor.hcahealthcare.com/events-and-presentations.

About the Company

As of September 30, 2021, HCA Healthcare operated 183 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2021, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) developments related to COVID-19, including, without limitation, the length and severity of the pandemic and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume of COVID-19 patients cared for across our health systems; measures we are taking to respond to the COVID-19 pandemic; the impact and terms of government and administrative regulation and stimulus (including the Families First Coronavirus Response Act, the CARES Act, the Paycheck Protection Program and Health Care Enhancement Act, the Consolidated Appropriations Act, 2021, the American Rescue Plan Act of 2021 and other enacted and potential future legislation); changes in revenues due to declining patient volumes, changes in payer mix and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions; and the timing, availability and adoption of effective medical treatments and vaccines, (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective, (3) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), including the effects of changes or court challenges to the Affordable Care Act or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, including proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), and also including any such laws or governmental regulations which are adopted in response to the COVID-19 pandemic, (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions, and those required under the Pay-As-You-Go Act of 2010 (“PAYGO Act”) as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) the highly competitive nature of the health care business, (9) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (10) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (11) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (12) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, including economic and business conditions (and the impact thereof on the economy, financial markets and banking industry) resulting from the COVID-19 pandemic, (16) the emergence of and effects related to other pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of potential cybersecurity incidents or security breaches, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (25) changes in the U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
Third Quarter
(Dollars in millions, except per share amounts)
 
 
 

2021

 

2020

Amount

 

Ratio

 

Amount

 

Ratio

 
Revenues

$

15,276

 

100.0

 

%

$

13,311

 

100.0

 

%

 
Salaries and benefits

 

7,094

 

46.4

 

 

6,097

 

45.8

 

Supplies

 

2,463

 

16.1

 

 

2,128

 

16.0

 

Other operating expenses

 

2,530

 

16.6

 

 

2,251

 

16.9

 

Government stimulus income reversal

 

-

 

-

 

 

822

 

6.2

 

Equity in earnings of affiliates

 

(35

)

(0.2

)

 

(40

)

(0.3

)

Depreciation and amortization

 

716

 

4.7

 

 

694

 

5.2

 

Interest expense

 

398

 

2.6

 

 

385

 

2.9

 

Gains on sales of facilities

 

(1,047

)

(6.9

)

 

(14

)

(0.1

)

 

 

12,119

 

79.3

 

 

12,323

 

92.6

 

 
Income before income taxes

 

3,157

 

20.7

 

 

988

 

7.4

 

 
Provision for income taxes

 

685

 

4.5

 

 

209

 

1.5

 

 
Net income

 

2,472

 

16.2

 

 

779

 

5.9

 

 
Net income attributable to noncontrolling interests

 

203

 

1.3

 

 

111

 

0.9

 

 
Net income attributable to HCA Healthcare, Inc.

$

2,269

 

14.9

 

$

668

 

5.0

 

 
Diluted earnings per share

$

7.00

 

$

1.95

 

 
Shares used in computing diluted earnings per share (millions)

 

324.029

 

 

343.346

 

 
Comprehensive income attributable to HCA Healthcare, Inc.

$

2,252

 

$

715

 

 
 
HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
For the Nine Months Ended September 30, 2021 and 2020
(Dollars in millions, except per share amounts)
 
 
 

2021

 

2020

Amount

 

Ratio

 

Amount

 

Ratio

 
Revenues

$

43,688

 

100.0

 

%

$

37,240

 

100.0

 

%
 
Salaries and benefits

 

19,780

 

45.3

 

 

17,545

 

47.1

 

Supplies

 

7,067

 

16.2

 

 

5,999

 

16.1

 

Other operating expenses

 

7,424

 

17.0

 

 

6,825

 

18.3

 

Equity in earnings of affiliates

 

(78

)

(0.2

)

 

(48

)

(0.1

)

Depreciation and amortization

 

2,125

 

4.8

 

 

2,059

 

5.6

 

Interest expense

 

1,168

 

2.7

 

 

1,201

 

3.2

 

Losses (gains) on sales of facilities

 

(1,057

)

(2.4

)

 

6

 

-

 

Losses on retirement of debt

 

12

 

-

 

 

295

 

0.8

 

 

 

36,441

 

83.4

 

 

33,882

 

91.0

 

 
Income before income taxes

 

7,247

 

16.6

 

 

3,358

 

9.0

 

 
Provision for income taxes

 

1,531

 

3.5

 

 

665

 

1.8

 

 
Net income

 

5,716

 

13.1

 

 

2,693

 

7.2

 

 
Net income attributable to noncontrolling interests

 

574

 

1.3

 

 

365

 

0.9

 

 
Net income attributable to HCA Healthcare, Inc

$

5,142

 

11.8

 

$

2,328

 

6.3

 

 
Diluted earnings per share

$

15.43

 

$

6.79

 

 
Shares used in computing diluted earnings per share (millions)

 

333.248

 

 

343.014

 

 
Comprehensive income attributable to HCA Healthcare, Inc.

$

5,152

 

$

2,273

 

HCA Healthcare, Inc.
Condensed Consolidated Balance Sheets
(Dollars in millions)
 
 
 

September 30,

 

June 30,

 

December 31,

2021

 

2021

 

2020

 
ASSETS
Current assets:
Cash and cash equivalents

$

1,027

 

$

1,120

 

$

1,793

 

Accounts receivable

 

8,433

 

 

7,636

 

 

7,051

 

Inventories

 

2,019

 

 

2,027

 

 

2,025

 

Other

 

1,769

 

 

1,692

 

 

1,464

 

 

13,248

 

 

12,475

 

 

12,333

 

 
Property and equipment, at cost

 

50,695

 

 

50,698

 

 

49,317

 

Accumulated depreciation

 

(27,148

)

 

(27,227

)

 

(26,118

)

 

23,547

 

 

23,471

 

 

23,199

 

 
Investments of insurance subsidiaries

 

418

 

 

410

 

 

388

 

Investments in and advances to affiliates

 

412

 

 

382

 

 

422

 

Goodwill and other intangible assets

 

9,153

 

 

8,680

 

 

8,578

 

Right-of-use operating lease assets

 

2,099

 

 

2,118

 

 

2,024

 

Other

 

685

 

 

628

 

 

546

 

 

$

49,562

 

$

48,164

 

$

47,490

 

 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable

$

3,759

 

$

3,531

 

$

3,535

 

Accrued salaries

 

2,134

 

 

1,896

 

 

1,720

 

Other accrued expenses

 

3,481

 

 

2,935

 

 

3,240

 

Long-term debt due within one year

 

250

 

 

253

 

 

209

 

 

9,624

 

 

8,615

 

 

8,704

 

 
Long-term debt, less debt issuance costs and discounts of $253, $255 and $236

 

32,049

 

 

32,319

 

 

30,795

 

Professional liability risks

 

1,522

 

 

1,585

 

 

1,486

 

Right-of-use operating lease obligations

 

1,742

 

 

1,767

 

 

1,673

 

Income taxes and other liabilities

 

2,800

 

 

2,088

 

 

1,940

 

 
Stockholders' equity:
Stockholders' (deficit) equity attributable to HCA Healthcare, Inc.

 

(695

)

 

(593

)

 

572

 

Noncontrolling interests

 

2,520

 

 

2,383

 

 

2,320

 

 

1,825

 

 

1,790

 

 

2,892

 

$

49,562

 

$

48,164

 

$

47,490

 

 
HCA Healthcare, Inc.
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended September 30, 2021 and 2020
(Dollars in millions)
 
 
 

2021

2020

 
Cash flows from operating activities:
Net income

$

5,716

 

$

2,693

 

Adjustments to reconcile net income to net cash provided by operating activities:
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable

 

(1,312

)

 

930

 

Inventories and other assets

 

(333

)

 

(36

)

Accounts payable and accrued expenses

 

731

 

 

542

 

Government stimulus refund liability

 

-

 

 

6,123

 

Depreciation and amortization

 

2,125

 

 

2,059

 

Income taxes

 

185

 

 

(114

)

Losses (gains) on sales of facilities .

 

(1,057

)

 

6

 

Losses on retirement of debt

 

12

 

 

295

 

Amortization of debt issuance costs and discounts

 

21

 

 

22

 

Share-based compensation

 

341

 

 

229

 

Other

 

87

 

 

66

 

 
Net cash provided by operating activities

 

6,516

 

 

12,815

 

 
 
Cash flows from investing activities:
Purchase of property and equipment

 

(2,385

)

 

(2,087

)

Acquisition of hospitals and health care entities

 

(488

)

 

(380

)

Sales of hospitals and health care entities

 

1,980

 

 

68

 

Change in investments

 

(38

)

 

(40

)

Other

 

2

 

 

(44

)

 
Net cash used in investing activities

 

(929

)

 

(2,483

)

 
 
Cash flows from financing activities:
Issuances of long-term debt

 

4,337

 

 

2,700

 

Net change in revolving credit facilities

 

500

 

 

(2,480

)

Repayment of long-term debt

 

(3,787

)

 

(3,403

)

Distributions to noncontrolling interests

 

(501

)

 

(393

)

Payment of debt issuance costs

 

(38

)

 

(35

)

Payment of dividends

 

(476

)

 

(153

)

Repurchase of common stock

 

(6,143

)

 

(441

)

Other

 

(241

)

 

(156

)

 
Net cash used in financing activities

 

(6,349

)

 

(4,361

)

 
Effect of exchange rate changes on cash and cash equivalents

 

(4

)

 

(4

)

 
Change in cash and cash equivalents

 

(766

)

 

5,967

 

Cash and cash equivalents at beginning of period

 

1,793

 

 

621

 

 
 
Cash and cash equivalents at end of period

$

1,027

 

$

6,588

 

 
 
Interest payments

$

1,127

 

$

1,230

 

Income tax payments, net

$

1,346

 

$

779

 

 

HCA Healthcare, Inc.

Operating Statistics

 

 

 

 

For the Nine Months

Third Quarter

 

 

Ended September 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2021

 

2020

 

2021

 

2020

Operations:
Number of Hospitals

 

183

 

 

187

 

 

183

 

 

187

 

Number of Freestanding Outpatient Surgery Centers*

 

123

 

 

121

 

 

123

 

 

121

 

Licensed Beds at End of Period

 

48,950

 

 

49,473

 

 

48,950

 

 

49,473

 

Weighted Average Beds in Service

 

42,088

 

 

42,426

 

 

42,304

 

 

42,304

 

Reported:
 
Admissions

 

536,848

 

 

506,756

 

 

1,575,269

 

 

1,487,992

 

% Change

 

5.9

%

 

5.9

%

Equivalent Admissions

 

905,627

 

 

835,576

 

 

2,654,328

 

 

2,447,747

 

% Change

 

8.4

%

 

8.4

%

Revenue per Equivalent Admission

$

16,868

 

$

15,930

 

$

16,459

 

$

15,214

 

% Change

 

5.9

%

 

8.2

%

Inpatient Revenue per Admission

$

18,102

 

$

16,265

 

$

17,115

 

$

15,531

 

% Change

 

11.3

%

 

10.2

%

 
Patient Days

 

2,865,220

 

 

2,593,139

 

 

8,166,211

 

 

7,476,794

 

% Change

 

10.5

%

 

9.2

%

Equivalent Patient Days

 

4,833,197

 

 

4,275,481

 

 

13,760,066

 

 

12,299,326

 

% Change

 

13.0

%

 

11.9

%

 
Inpatient Surgery Cases

 

126,436

 

 

133,492

 

 

390,486

 

 

387,228

 

% Change

 

-5.3

%

 

0.8

%

Outpatient Surgery Cases

 

249,192

 

 

232,493

 

 

742,527

 

 

629,723

 

% Change

 

7.2

%

 

17.9

%

 
Emergency Room Visits

 

2,338,180

 

 

1,813,661

 

 

6,308,386

 

 

5,594,484

 

% Change

 

28.9

%

 

12.8

%

 
Outpatient Revenues as a Percentage of Patient Revenues

 

34.1

%

 

35.5

%

 

36.0

%

 

35.0

%

 
Average Length of Stay (days)

 

5.337

 

 

5.117

 

 

5.184

 

 

5.025

 

 
Occupancy (weighted average beds in service)

 

74.0

%

 

66.4

%

 

70.7

%

 

64.5

%

 
Same Facility:
 
Admissions

 

531,032

 

 

497,309

 

 

1,549,732

 

 

1,458,609

 

% Change

 

6.8

%

 

6.2

%

Equivalent Admissions

 

892,665

 

 

817,079

 

 

2,603,550

 

 

2,392,119

 

% Change

 

9.3

%

 

8.8

%

Revenue per Equivalent Admission

$

16,799

 

$

15,962

 

$

16,456

 

$

15,247

 

% Change

 

5.2

%

 

7.9

%

Inpatient Revenue per Admission

$

18,055

 

$

16,323

 

$

17,148

 

$

15,610

 

% Change

 

10.6

%

 

9.9

%

 
Inpatient Surgery Cases

 

125,533

 

 

131,957

 

 

386,190

 

 

382,121

 

% Change

 

-4.9

%

 

1.1

%

Outpatient Surgery Cases

 

242,450

 

 

227,918

 

 

724,914

 

 

616,082

 

% Change

 

6.4

%

 

17.7

%

 
Emergency Room Visits

 

2,301,968

 

 

1,753,887

 

 

6,162,206

 

 

5,419,887

 

% Change

 

31.2

%

 

13.7

%

* Excludes freestanding endoscopy centers (21 centers at both September 30, 2021 and September 30, 2020).
HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
Operating Results Summary
(Dollars in millions, except per share amounts)
 
 

 

 

 

 

For the Nine Months

Third Quarter

 

Ended September 30,

2021

 

2020

 

2021

 

2020

 
Revenues

$

15,276

 

$

13,311

 

$

43,688

 

$

37,240

 

 
Net income attributable to HCA Healthcare, Inc.

$

2,269

 

$

668

 

$

5,142

 

$

2,328

 

Losses (gains) on sales of facilities (net of tax)

 

(788

)

 

(10

)

 

(795

)

 

9

 

Losses on retirement of debt (net of tax)

 

-

 

 

-

 

 

9

 

 

227

 

 
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a)

 

1,481

 

 

658

 

 

4,356

 

 

2,564

 

Depreciation and amortization

 

716

 

 

694

 

 

2,125

 

 

2,059

 

Interest expense

 

398

 

 

385

 

 

1,168

 

 

1,201

 

Provision for income taxes

 

426

 

 

205

 

 

1,272

 

 

730

 

Net income attributable to noncontrolling interests

 

203

 

 

111

 

 

574

 

 

365

 

 
Adjusted EBITDA (a)

$

3,224

 

$

2,053

 

$

9,495

 

$

6,919

 

 
Adjusted EBITDA margin (a)

 

21.1

%

 

15.4

%

 

21.7

%

 

18.6

%

 
Diluted earnings per share:
Net income attributable to HCA Healthcare, Inc.

$

7.00

 

$

1.95

 

$

15.43

 

$

6.79

 

Losses (gains) on sales of facilities

 

(2.43

)

 

(0.03

)

 

(2.39

)

 

0.03

 

Losses on retirement of debt

 

-

 

 

-

 

 

0.03

 

 

0.66

 

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a)

$

4.57

 

$

1.92

 

$

13.07

 

$

7.48

 

 
Shares used in computing diluted earnings per share (millions)

 

324.029

 

 

343.346

 

 

333.248

 

 

343.014

 

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

 

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.

 

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
2021 Operating Results Forecast
(Dollars in millions, except per share amounts)
 
 

For the Year Ending

December 31, 2021

Low

 

High

 
Revenues

$

58,700

$

59,300

 
Net income attributable to HCA Healthcare, Inc. (a)

$

5,650

$

5,830

Depreciation and amortization

 

2,840

 

2,860

Interest expense

 

1,560

 

1,580

Provision for income taxes

 

1,700

 

1,750

Net income attributable to noncontrolling interests

 

750

 

780

 
Adjusted EBITDA (a) (b)

$

12,500

$

12,800

 
Diluted earnings per share:
Net income attributable to HCA Healthcare, Inc.

$

17.20

$

17.80

 
Shares used in computing diluted earnings per share (millions)

 

329.000

 

329.000

 
The Company's forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.
 
 

(a)

The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy.

 

(b)

Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams.

 

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.

 

Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.

 

INVESTOR CONTACT:

Mark Kimbrough

615-344-2688

MEDIA CONTACT:

Harlow Sumerford

615-344-1851

Source: HCA Healthcare

FAQ

What were HCA's revenues for the third quarter of 2021?

HCA's revenues for the third quarter of 2021 totaled $15.276 billion.

What was the net income reported by HCA for Q3 2021?

HCA reported a net income of $2.269 billion or $7.00 per diluted share for the third quarter of 2021.

How did HCA's Adjusted EBITDA change in Q3 2021?

HCA's Adjusted EBITDA for the third quarter of 2021 was $3.224 billion, up from $2.053 billion in 2020.

What is the declared dividend per share by HCA for Q4 2021?

HCA declared a quarterly cash dividend of $0.48 per share, to be paid on December 29, 2021.

What is HCA's revised revenue guidance for 2021?

HCA revised its 2021 revenue guidance to between $58.7 billion and $59.3 billion.

HCA Healthcare, Inc.

NYSE:HCA

HCA Rankings

HCA Latest News

HCA Stock Data

84.57B
181.11M
28.43%
63.6%
1.02%
Medical Care Facilities
Services-general Medical & Surgical Hospitals, Nec
Link
United States of America
NASHVILLE